Phase II clinical trial of low dose dasatinib in patients with resistant or intolerant chronic myeloid leukemia who are treated with low lose imatinib
Phase 2
Recruiting
- Conditions
- Chronic myeloid leukemia patients in chronic phase who are refractory or resistant to low dose imatinib therapy.
- Registration Number
- JPRN-UMIN000003499
- Lead Sponsor
- Kanto CML Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion Criteria: Concurrent malignancy other than CML Women who are pregnant or breastfeeding Concurrent pleural effusion Uncontrolled or significant cardiovascular disease A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy. Prior therapy with dasatinib Subjects with T315I and/or F317L BCR-ABL point mutations
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The ratio of patients who achieved major molecular response (MMR) after 12 months of dasatinib therapy.
- Secondary Outcome Measures
Name Time Method